In the case of studies conducted on mouse asthma models, it has been shown that the use of HMGB1 neutralizing antibody reduces the production of Th1, Th2, and Th17 cells, which has a significant effect on the weakening of respiratory tract inflammation or mucus formation [61]. Here, HMGB1 is linked to asthma.